Ustekinumab v. Enbrel data

Johnson & Johnson (NYSE:JNJ) said both doses of ustekinumab were superior vs. Enbrel etanercept in treating chronic moderate to severe psoriasis in a single-blind, head-to-head Phase III trial in 903 patients. Patients received 45 or 90 mg of subcutaneous ustekinumab at weeks 0 and 4 or twice-weekly 50 mg subcutaneous Enbrel for 12 weeks. ...